دورية أكاديمية
أعرض في EDS

Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.

التفاصيل البيبلوغرافية
العنوان: Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV.
المؤلفون: Liu WD; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan. Electronic address: b95401043@ntu.edu.tw., Lin MS; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: mslin1221@ntu.edu.tw., Sun HY; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hysun13@gmail.com., Shih MC; School of Medicine, National Tsing Hua University, Hsinchu, Taiwan. Electronic address: mcshih@gms.ndhu.edu.tw., Chuang YC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: weischuang@gmail.com., Huang YS; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: b101091021@gmail.com., Lin KY; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: kuanyin0828@gmail.com., Li GC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: ligc2020n@gmail.com., Wu PY; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: wpei.ying@msa.hinet.net., Chen LY; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: pazigid@ntuh.gov.tw., Liu WC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: lwj0925@gmail.com., Su YC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: echinsu@gmail.com., He PC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: vicky90180@gmail.com., Chen YT; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: et771205@gmail.com., Lin CY; Department of Nursing, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: 107545@ntuh.gov.tw., Cheng YC; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: xking54647@gmail.com., Yao Y; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: mouse.ohya@gmail.com., Yeh YC; Department of Nursing, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: r08426007@ntu.edu.tw., Liu CC; Department of Nursing, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: kendochi@yahoo.com.tw., Pan MY; Department of Nursing, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: 007520@ntuh.gov.tw., Luo YZ; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: ruru987654321@hotmail.com., Chang HY; Center of Infection Control, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: a0956180125@gmail.com., Wang JT; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan. Electronic address: wang.jt1968@gmail.com., Sheng WH; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; School of Medicine, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: whsheng@ntu.edu.tw., Hsieh SM; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hsmaids@hotmail.com., Chang SY; Department of Clinical Laboratory Sciences and Medical Biotechnology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: sychang@ntu.edu.tw., Hung CC; Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin County, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: hcc0401@ntu.edu.tw.
المصدر: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi [J Microbiol Immunol Infect] 2024 Aug; Vol. 57 (4), pp. 554-563. Date of Electronic Publication: 2024 Feb 26.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: published by Elsevier for the Taiwan Society of Microbiology Country of Publication: England NLM ID: 100956211 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1995-9133 (Electronic) Linking ISSN: 16841182 NLM ISO Abbreviation: J Microbiol Immunol Infect Subsets: MEDLINE
أسماء مطبوعة: Publication: Feb. 2010- : Oxford, England : published by Elsevier for the Taiwan Society of Microbiology
Original Publication: Taipei, Taiwan : Chinese Society of Microbiology : Chinese Society of Immunology [and] : Infectious Diseases Society of the Republic of China,
مواضيع طبية MeSH: COVID-19*/prevention & control , COVID-19*/immunology , Antibodies, Viral*/blood , HIV Infections*/immunology , Spike Glycoprotein, Coronavirus*/immunology , BNT162 Vaccine*/administration & dosage , BNT162 Vaccine*/immunology , SARS-CoV-2*/immunology , Immunoglobulin G*/blood , 2019-nCoV Vaccine mRNA-1273*/immunology , 2019-nCoV Vaccine mRNA-1273*/administration & dosage , COVID-19 Vaccines*/immunology , COVID-19 Vaccines*/administration & dosage, Humans ; Male ; Female ; Middle Aged ; Adult ; Vaccination/methods ; Vaccine Efficacy ; Seroconversion
مستخلص: Background: Real-world vaccine effectiveness following the third dose of vaccination against SARS-CoV-2 remains less investigated among people with HIV (PWH).
Methods: PWH receiving the third dose of BNT162b2 and mRNA-1273 (either 50- or 100-μg) were enrolled. Participants were followed for 180 days until the fourth dose of COVID-19 vaccination, SARS-CoV-2 infection, seroconversion of anti-nucleocapsid IgG, death, or loss to follow-up. Anti-spike IgG was determined every 1-3 months.
Results: Of 1427 participants undergoing the third-dose COVID-19 vaccination, 632 (44.3%) received 100-μg mRNA-1273, 467 (32.8%) 50-μg mRNA-1273, and 328 (23.0%) BNT162b2 vaccine and the respective rate of SARS-CoV-2 infection or seroconversion of anti-nucleocapsid IgG was 246.1, 280.8 and 245.2 per 1000 person-months of follow-up (log-rank test, p = 0.28). Factors associated with achieving anti-S IgG titers >1047 BAU/mL included CD4 count <200 cells/mm 3 (adjusted odds ratio [aOR], 0.11; 95% CI, 0.04-0.31), plasma HIV RNA >200 copies/mL (aOR, 0.27; 95% CI, 0.09-0.80), having achieved anti-spike IgG >141 BAU/mL within 3 months after primary vaccination (aOR, 3.69; 95% CI, 2.68-5.07), receiving BNT162b2 vaccine as the third dose (aOR, 0.20; 95% CI, 0.10-0.41; reference, 100-μg mRNA-1273), and having previously received two doses of mRNA vaccine in primary vaccination (aOR, 2.46; 95% CI, 1,75-3.45; reference, no exposure to mRNA vaccine).
Conclusions: PWH receiving different types of the third dose of COVID-19 vaccine showed similar vaccine effectiveness against SARS-CoV-2 infection. An additional dose with 100-μg mRNA-1273 could generate a higher antibody response than with 50-μg mRNA-1273 and BNT162b2 vaccine.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
فهرسة مساهمة: Keywords: BNT162b2 vaccine; Booster vaccination; Humoral immunity; Immunogenicity; Serologic response; mRNA-1273 vaccine
المشرفين على المادة: 0 (Antibodies, Viral)
0 (Spike Glycoprotein, Coronavirus)
0 (BNT162 Vaccine)
0 (Immunoglobulin G)
0 (spike protein, SARS-CoV-2)
EPK39PL4R4 (2019-nCoV Vaccine mRNA-1273)
0 (COVID-19 Vaccines)
تواريخ الأحداث: Date Created: 20240301 Date Completed: 20240810 Latest Revision: 20240810
رمز التحديث: 20240812
DOI: 10.1016/j.jmii.2024.02.004
PMID: 38429206
قاعدة البيانات: MEDLINE
الوصف
تدمد:1995-9133
DOI:10.1016/j.jmii.2024.02.004